FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376132695> ?p ?o ?g. }

• W4376132695 endingPage "e001360" @default.
• W4376132695 startingPage "e001360" @default.
• W4376132695 abstract "Cystic fibrosis (CF) is a multisystem condition that is complicated by recurrent pulmonary infections requiring aggressive antibiotic treatment. This predisposes the patient to complications such as sensorineural hearing loss, renal impairment, hypersensitivity and the development of antibiotic resistance. Pseudomonas aeruginosa is one of the more common organisms which cause recurrent infections and result in greater morbidity and mortality in people living with CF. Bacteriophages have been identified as a potential alternative or adjunct to antibiotics. We hypothesise that bacteriophage therapy is a safe and well-tolerated treatment in children with CF infected with P. aeruginosa infection in their airways.This single-arm, open-labelled, non-randomised trial will run for a maximum period of 36 months with up to 10 participants. Adolescents (≥12 years and <18 years of age) who continue to shed P.aeruginosa (within 3 months of enrolment) despite undergoing eradication therapy previously, will be considered for this trial. Non-genetically modified bacteriophages that have demonstrated obligate lytic activity against each of the study participants' P. aeruginosa strains will be selected and prepared according to a combination of established protocols (isolation, purification, sterility testing and packaging) to achieve close to good manufacturing practice recommendations. The selected bacteriophage will be administered endo-bronchially first under direct vision, followed by two times a day nebulisation for 7 days in addition to standard CF treatment (intravenous antibiotics, physiotherapy to be completed as inpatient for 10-14 days). Safety and tolerability will be defined as the absence of (1) fever above 38.5°C occurring within 1 hour of the administration of the nebulised bacteriophage, (2) a 10% decline in spirometry (forced expiratory volume in 1 s %) measured preadministration and postadministration of the first dose of nebulised bacteriophage. Clinical reviews including repeat sputum cultures and spirometry will be performed at 3, 6, 9 and 12 months following bacteriophage treatment.Our clinical trial is conducted in accordance with (1) good clinical practice, (2) Australian legislation, (3) National Health and Medical Research Council guidelines for the ethical conduct of research.Australia and New Zealand Clinical Trial Registry (ACTRN12622000767707)." @default.
• W4376132695 created "2023-05-12" @default.
• W4376132695 creator A5008622688 @default.
• W4376132695 creator A5016936541 @default.
• W4376132695 creator A5019627827 @default.
• W4376132695 creator A5052262069 @default.
• W4376132695 creator A5055346025 @default.
• W4376132695 creator A5071119529 @default.
• W4376132695 creator A5071449057 @default.
• W4376132695 date "2023-05-01" @default.
• W4376132695 modified "2023-10-04" @default.
• W4376132695 title "Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and<i>Pseudomonas aeruginosa</i>" @default.
• W4376132695 cites W1775281360 @default.
• W4376132695 cites W1964720125 @default.
• W4376132695 cites W1971558827 @default.
• W4376132695 cites W1982069914 @default.
• W4376132695 cites W1985035909 @default.
• W4376132695 cites W1992101332 @default.
• W4376132695 cites W1998779544 @default.
• W4376132695 cites W2008378835 @default.
• W4376132695 cites W2016897911 @default.
• W4376132695 cites W2026733066 @default.
• W4376132695 cites W2030716514 @default.
• W4376132695 cites W2047582511 @default.
• W4376132695 cites W2063345973 @default.
• W4376132695 cites W2076706379 @default.
• W4376132695 cites W2081360802 @default.
• W4376132695 cites W2086235445 @default.
• W4376132695 cites W2088849723 @default.
• W4376132695 cites W2090817404 @default.
• W4376132695 cites W2093086300 @default.
• W4376132695 cites W2097999790 @default.
• W4376132695 cites W2117604880 @default.
• W4376132695 cites W2128912840 @default.
• W4376132695 cites W2133707787 @default.
• W4376132695 cites W2140801627 @default.
• W4376132695 cites W2148491414 @default.
• W4376132695 cites W2151224434 @default.
• W4376132695 cites W2161006889 @default.
• W4376132695 cites W2171593498 @default.
• W4376132695 cites W2189116376 @default.
• W4376132695 cites W2296724767 @default.
• W4376132695 cites W2399110743 @default.
• W4376132695 cites W2404138590 @default.
• W4376132695 cites W2417933242 @default.
• W4376132695 cites W2462085581 @default.
• W4376132695 cites W2465973360 @default.
• W4376132695 cites W2499232252 @default.
• W4376132695 cites W2508337372 @default.
• W4376132695 cites W2533199225 @default.
• W4376132695 cites W2549976854 @default.
• W4376132695 cites W2606951746 @default.
• W4376132695 cites W2736809256 @default.
• W4376132695 cites W2743296461 @default.
• W4376132695 cites W2783669395 @default.
• W4376132695 cites W2800035215 @default.
• W4376132695 cites W2804511674 @default.
• W4376132695 cites W2885904114 @default.
• W4376132695 cites W2889185703 @default.
• W4376132695 cites W2905025743 @default.
• W4376132695 cites W2909378168 @default.
• W4376132695 cites W2911362701 @default.
• W4376132695 cites W2924638868 @default.
• W4376132695 cites W2943878465 @default.
• W4376132695 cites W2950541901 @default.
• W4376132695 cites W2961215432 @default.
• W4376132695 cites W2969292884 @default.
• W4376132695 cites W2981067716 @default.
• W4376132695 cites W3007565704 @default.
• W4376132695 cites W3042292116 @default.
• W4376132695 cites W3045043630 @default.
• W4376132695 cites W3114901734 @default.
• W4376132695 cites W3118458503 @default.
• W4376132695 cites W3120225898 @default.
• W4376132695 cites W3154381322 @default.
• W4376132695 cites W3163530362 @default.
• W4376132695 cites W3175417702 @default.
• W4376132695 cites W3178034838 @default.
• W4376132695 cites W3202964367 @default.
• W4376132695 cites W4319054156 @default.
• W4376132695 doi "https://doi.org/10.1136/bmjresp-2022-001360" @default.
• W4376132695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37160359" @default.
• W4376132695 hasPublicationYear "2023" @default.
• W4376132695 type Work @default.
• W4376132695 citedByCount "2" @default.
• W4376132695 countsByYear W43761326952023 @default.
• W4376132695 crossrefType "journal-article" @default.
• W4376132695 hasAuthorship W4376132695A5008622688 @default.
• W4376132695 hasAuthorship W4376132695A5016936541 @default.
• W4376132695 hasAuthorship W4376132695A5019627827 @default.
• W4376132695 hasAuthorship W4376132695A5052262069 @default.
• W4376132695 hasAuthorship W4376132695A5055346025 @default.
• W4376132695 hasAuthorship W4376132695A5071119529 @default.
• W4376132695 hasAuthorship W4376132695A5071449057 @default.
• W4376132695 hasBestOaLocation W43761326951 @default.
• W4376132695 hasConcept C104317684 @default.
• W4376132695 hasConcept C126322002 @default.
• W4376132695 hasConcept C177713679 @default.

• next